🇺🇸 FDA
Patent

US 9617596

Biomarkers predictive for clinical response for glatiramer acetate

granted A61PA61P25/00A61P25/02

Quick answer

US patent 9617596 (Biomarkers predictive for clinical response for glatiramer acetate) held by TEVA PHARMACEUTICAL INDUSTRIES, LTD. expires Mon Apr 06 2037 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
TEVA PHARMACEUTICAL INDUSTRIES, LTD.
Grant date
Tue Apr 11 2017 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Apr 06 2037 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
19
CPC classes
A61P, A61P25/00, A61P25/02, A61P25/28